Shares in Amgen (NSDQ:AMGN) fell today even though the biotech topped expectations on Wall Street with its second quarter results.
The Thousand Oaks, Calif.-based company posted profits of $2.2 million, or $2.91 per share, on sales of $5.8 billion for the 3 months ended June 30, for bottom-line growth of 15% on sales growth of 2% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.